The combination of blue dye and radioisotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: a systematic review

He, Pei-Sheng; Li, Feng; Li, Guan-Hua; Guo, Can; Chen, Tian-Jin

doi:10.1186/s12885-016-2137-0

Table 1 Characteristics of included studies

From: The combination of blue dye and radioisotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: a systematic review

Author (year)	Design	Location	Sample size	Age	Clinical node status	NAC use	Radioisotope type	Blue dye type	Site of Blue dye	Site of isotope	Positive Preo LSG, No. (%)
Bass et al. (1999) [18]	NPS	USA	700	58	Unknown	Unknown	Filtered ^99mTc-sulfur colloid	Isosulfan	Intraparenchymal	Intraparenchymal	Unknown
Mariani et al. (2000) [28]	NPS	Italy	284	59	Mixed	Unknown	^99mTc-human albumin	Patent blue	Subdermal	Subdermal	Unknown
Rahusen et al. (2000) [30]	NPS	Netherlands	115	54	Unknown	Unknown	^99mTc-human albumin	Patent blue	intradermal	Intraparenchymal	105/115 (91 %)
Derossis et al. (2001) [12]	NPS	USA	2000	Unknown	Negative	Unknown	Unfiltered ^99mTc-sulfur colloid	Isosulfan	Intraparenchymal	Intradermal	Unknown
Bauer et al. (2002) [19]	NPS	USA	332	55	Negative	Unknown	Filtered ^99mTc-sulfur colloid	Isosulfan	Subareolar versus peritumoral	Peritumoral	195/223 (87.4 %)
Ahrendt et al. (2002) [17]	NPS	USA	174	59	Negative	Unknown	Filtered ^99mTc-sulfur colloid	Isosulfan	Intraparenchymal	Intraparenchymal	Unknown
Tsunoda et al. (2002) [34]	NPS	Japan	376	Unknown	Mixed	No	Tin colloid or phytate	Unknown	Subareolar or peritumoral	Peritumoral	Unknown
Pelosi et al. (2003) [29]	NPS	Italy	150	62	NA	Unknown	^99mTc-labelled Nanocoll	Isosulfan	Periareolar or subdermal	Periareolar or subdermal	93/100 (93 %)
Fleming et al. (2003) [22]	NPS	Ireland	125	≈56	Negative	Unknown	Radiocolloid isotope	Isosulfan	Periareolar	Intraparenchymal versus intradermal	103/125 (82.4 %)
Schirrmeister et al. (2004) [32]	NPS	Germany	814	58	62.9 % negative	Unknown	Radioactive colloid	Isosulfan or patent blue	Optional	Optional	Unknown
Lauridsen et al. (2004) [24]	NPS	Denmark	124	56	Negative	Unknown	^99mTc-human albumin	Patent blue	Peritumoral	Peritumoral	Unknown
Mamounas et al. (2005) [27]	RCT	USA	428	Unknown	76.2 % negative	Yes	Unknown	Isosulfan	Unknown	Unknown	Unknown
Takei et al. (2006) [33]	NPS	Japan	308	55	Negative	Unknown	^99mTc-phytate	Patent blue	Subdermal	Subdermal	Unknown
Argon et al. (2006) [1]	NPS	Turkey	100	48	Negative	No	^99mTc-tin colloid	Isosulfan	Intraparenchymal	Intradermal	90/100 (90 %)
Low et al. (2006) [26]	NPS	Australia	113	56	Negative	Unknown	^99mTc-sulfur colloid	Patent blue	Intradermal or subdermal	Peritumoral	97/113 (85.8 %)
Goyal et al. (2006) [23]	RCT	UK	842	18–80	Negative	Unknown	^99mTc-albumin colloid	Patent blue	Peritumoral	Peritumoral	490/707 (69.3 %)
Lelievre et al. (2007) [25]	NPS	France	152	57	Unknown	Unknown	^99mTc-sulfur colloid	Patent blue	Subareolar or peritumoral	Intradermal and intraparenchymal	149/152 (98 %)
Rodier et al. (2007) [31]	RCT	France	449	25–90	Negative	No	^99mTc-sulfur colloid	Patent blue	Peritumoral versus periareolar	Peritumoral versus periareolar	353/432 (81.7 %)
Kang et al. (2010) [10]	NPS	USA	3402	56	Negative	Mixed	^99mTc-sulfur colloid	Isosulfan	Unknown	Unknown	1566/1720 (91.0 %)
Johnson et al. (2011) [8]	NPS	USA	696	57	Unknown	Unknown	Unfiltered ^99mTc- sulfur colloid	Isosulfan	Subareolar	Subareolar	Unknown
Kuehn et al. (2013) [3]	NPS	Germany, Austria	1334	49	Negative	Mixed	Unknown	Unknown	Optional	Optional	1490/1614 (92.3 %)
Boughey et al. (2013) [20]	RCT	USA	689	49 (23–93)	Positive	Yes	Unknown	Isosulfan or methylene	Optional	Optional	Unknown
Elmadahm et al. (2015) [21]	RCT	Australia	1088	Unknown	Negative	No	^99mTc-sulfur colloid	Patent blue	Peritumoural	Peritumoural	779/957 (81.4 %)
O'Reilly et al. (2015) [11]	RCT	Ireland	667	48	Negative	No	Unknown	Isosulfan	Intradermal	Subdermal	667/667 (100 %)

FNR false-negative rate, LSG lymphoscintigraphy, NAC neoadjuvant chemotherapy, NPS non-randomized prospective study

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us